Novel oral anticoagulants may be effective and safe alternatives to conventional treatment for left ventricular (LV) mural thrombus. A case of left ventricular mural thrombus successfully treated with dabigatran etixelate is described, and the rationale for undertaking further systematic evaluation of novel anticoagulants for this indication discussed.
In patients with left ventricular (LV) mural thrombus the novel oral anticoagulants, which include the direct thrombin inhibitor dabigatran etixelate, may be effective and safe alternatives to conventional treatment with heparin and a vitamin K antagonist. However their use for this indication has not been reported. We describe a case and discuss the rationale for undertaking further systematic evaluation of novel anticoagulants for this indication.
View Pdf and Full TextIn patients with left ventricular (LV) mural thrombus the novel oral anticoagulants, which include the direct thrombin inhibitor dabigatran etixelate, may be effective and safe alternatives to conventional treatment with heparin and a vitamin K antagonist. However their use for this indication has not been reported. We describe a case and discuss the rationale for undertaking further systematic evaluation of novel anticoagulants for this indication.
View Journal of Case Reports and Studies (JCRS)
View all Journal of Case Reports and Studies articles
No comments:
Post a Comment